Xu Yaping, Chen Yan, Tan Jun Jie, Ooi Jer Ping, Guo Zhikun
USM-ALPS Joint Laboratory for Heart Research, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Kepala Batas, Pulau Pinang, Malaysia.
Henan Key Laboratory of Cardiac Reconstruction and Heart Transplantation, Zhengzhou the Seventh People's Hospital, Zhengzhou, 45300, Henan, P. R. China.
J Cardiovasc Transl Res. 2025 Feb;18(1):28-39. doi: 10.1007/s12265-024-10553-3. Epub 2024 Aug 20.
Intrapericardial administration has been proposed as an alternative delivery route of pharmacological agents via the bilaminar sac of pericardium surrounding the heart. To date, intrapericardial administration has entailed the localized administration of a broad spectrum of therapeutic agents. These agents include stem cells, extracellular matrix, growth factor, drugs, bioactive materials, and genetic materials, to the heart and coronary arteries. The route not only overcomes the limitations associated with traditional systemic administration methods, but also presents multiple intrinsic advantages over the other approaches, allowing greater therapeutic actions. Intrapericardial administration exhibits versatility in addressing certain cardiac conditions and ongoing research in this field certainly holds promise for further innovations and advancements to improve cardiac treatment. Thus, this review discusses the anatomy and physiology of the pericardium, the intrapericardial administration access routes, the recent application of intrapericardial delivery in the context of cardiac repair as well as the challenges associated with the approach.
心包内给药已被提议作为一种通过心脏周围心包的双层囊输送药物的替代途径。迄今为止，心包内给药需要对多种治疗剂进行局部给药。这些药剂包括干细胞、细胞外基质、生长因子、药物、生物活性材料和遗传物质，用于心脏和冠状动脉。该途径不仅克服了传统全身给药方法的局限性，而且与其他方法相比具有多种内在优势，能产生更大的治疗作用。心包内给药在治疗某些心脏疾病方面具有多功能性，该领域正在进行的研究无疑有望实现进一步的创新和进步，以改善心脏治疗。因此，本综述讨论了心包的解剖学和生理学、心包内给药途径、心包内给药在心脏修复方面的最新应用以及该方法相关的挑战。
